STOKHealthcare · BiotechnologyThe 14 Wall Street analysts covering Stoke Therapeutics, Inc. hold a median 12-month price target of $44 — +68.0% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 18 of 100 as at 31 Oct 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.
Consensus tells you what everyone already believes. The model scores Stoke Therapeutics, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (70): The shares have been drifting up relative to others.
Quality (16): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on STOK, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +68.0% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 21 Aug 2026 | JP Morgan | Reinstates | Overweight | $40 |
| 4 Aug 2026 | Canaccord Genuity | Maintains | Buy | $60 → $58 |
| 4 Aug 2026 | Canaccord Genuity | Maintains | Buy | — |
| 4 Aug 2026 | Chardan Capital | Maintains | Buy | — |
| 4 Aug 2026 | Chardan Capital | Maintains | Buy | $35 |
| 4 Aug 2026 | Guggenheim | Reiterates | Buy | — |
| 4 Aug 2026 | Guggenheim | Reiterates | Buy | $60 |
| 4 Aug 2026 | Wedbush | Maintains | Outperform | — |
| 4 Aug 2026 | Wedbush | Maintains | Outperform | $38 → $40 |
| 13 July 2026 | Goldman Sachs | Initiates | Buy | — |
| 13 July 2026 | Goldman Sachs | Initiates | Buy | $44 |
| 11 May 2026 | BTIG | Reiterates | Buy | — |
| 20 Mar 2026 | Canaccord Genuity | Maintains | Buy | — |
| 19 Mar 2026 | BTIG | Reiterates | Buy | — |
| 18 Mar 2026 | Chardan Capital | Maintains | Buy | — |
| 18 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 17 Mar 2026 | Needham | Maintains | Buy | — |
| 17 Mar 2026 | Wedbush | Maintains | Outperform | — |
| 24 Feb 2026 | Wolfe Research | Initiates | Outperform | — |
| 12 Jan 2026 | Wedbush | Maintains | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
STOK appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 30 Oct 2026, Stoke Therapeutics, Inc. returned −17.4% against +12.4% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 15% of US stocks
Cheaper than 4% of US stocks
Cheaper than 21% of US stocks
Cheaper than 83% of US stocks
Higher than 8% of US stocks
Higher than 15% of US stocks
Higher than 6% of US stocks
Higher than 30% of US stocks
Higher than 19% of US stocks
Higher than 12% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Stoke Therapeutics, Inc. has a market value of $1.7B and an enterprise value of $1.4B.
Revenue in the twelve months to 30 June 2026: $27.6M. The latest quarter shrank 32.5% year on year.
Net income over the same four quarters: −$207.9M, a −753.6% net margin.
Free cash flow in the twelve months to 30 June 2026: −$180.7M.
Trailing P/E: 48.8×; forward P/E: −7.4× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Stoke Therapeutics, Inc. employs 170 people — $162K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Stoke Therapeutics, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Seeking Alpha published a transcript of Stoke Therapeutics, Inc.’s Q3 2026 earnings call. The excerpt contains no further details about the call.
Why it matters — The transcript is a source of company commentary for STOK watchers, but the provided excerpt does not describe any specific updates.
Stoke Therapeutics said its Phase III EMPEROR trial of zorevunersen in Dravet syndrome is progressing toward a planned third-quarter 2027 data readout. The company is preparing for a potential U.S. regulatory submission later in 2027 and a possible early 2028 launch.
Why it matters — The update outlines the company's anticipated clinical and regulatory milestones for zorevunersen.
Stoke Therapeutics reported a quarterly loss of $1.08 per share, compared with the Zacks Consensus Estimate of a $0.88 loss and a $0.65 loss per share a year earlier. The headline says the company topped revenue estimates.
Why it matters — STOK watchers may note the reported per-share loss exceeded the consensus loss and was larger than a year ago.
Stoke Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided business updates. The excerpt identifies zorevunersen as its lead investigational medicine in development for Dravet syndrome.
Why it matters — The report covers the company’s quarterly financial results and updates on its development program, topics relevant to STOK watchers.
Stoke Therapeutics said management will host a webcast and conference call for analysts and investors on Thursday, October 29, 2026, at 4:30 p.m., to discuss third-quarter 2026 business and financial updates.
Why it matters — The event will provide STOK watchers with an opportunity to hear management discuss the company's business and financial updates.
The 14 Wall Street analysts covering Stoke Therapeutics, Inc. have a median 12-month price target of $44, with estimates ranging from $35 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Stoke Therapeutics, Inc., 14 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Stoke Therapeutics, Inc. 18 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 31 Oct 2026, Stoke Therapeutics, Inc. ranks 18 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (70 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies +68.0% from the last close, and Ticker Nerd's factor model ranks Stoke Therapeutics, Inc. 18 out of 100 as at 31 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Stoke Therapeutics, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for STOK are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $60 over the next 12 months.
Stoke Therapeutics, Inc. returned -17.4% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for severe genetic diseases.
The most recent item we track (Seeking Alpha, 30 Oct 2026): "Stoke Therapeutics, Inc. (STOK) Q3 2026 Earnings Call Transcript". Seeking Alpha published a transcript of Stoke Therapeutics, Inc.’s Q3 2026 earnings call. The excerpt contains no further details about the call.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing RNA-based medicines for severe genetic diseases. Its programs are designed to upregulate protein expression and address the underlying cause of disorders linked to insufficient protein production. The company’s portfolio centers on precision therapies for rare neuromuscular, neurological, and other haploinsufficiency-related conditions, with a strong emphasis on antisense oligonucleotide approaches and targeted gene output modulation. Stoke Therapeutics operates in the genetic medicines and rare disease markets, where its research platform supports the discovery and development of treatments intended to restore healthier levels of naturally occurring proteins. Headquartered in Bedford, Massachusetts, Stoke Therapeutics plays a specialized role in advancing novel therapeutic approaches for patients with complex inherited diseases.
CEO Mr. Ian F. Smith A.C.A., C.P.A. · 170 employees · United States · https://www.stoketherapeutics.com
